Figure 3.

Effect of Neoadjuvant GMCI on Activation Markers and Cytokine Production in CD8⁺ TILs

Using the same samples as described in Figure 2, the expression of three proliferation/activation markers (Ki67, CD38, and HLA-DR) on the CD8⁺ TILs in the pre-Rx samples were compared to post-Rx tumor samples. Paired t tests were applied to define the statistical significance (p value) of the changes. The upper right panel shows the comparison between the Ki67 expression in this trial compared to our lung cancer control samples. A Student’s t test was applied to define the statistical significance (p value) of the differences.